

# World Journal of *Gastrointestinal Oncology*

*World J Gastrointest Oncol* 2013 September 15; 5(9): 186-194





## Editorial Board

2011-2015

The *World Journal of Gastrointestinal Oncology* Editorial Board consists of 428 members, representing a team of worldwide experts in gastrointestinal oncology. They are from 40 countries, including Argentina (2), Australia (10), Belgium (5), Brazil (2), Canada (4), Chile (2), China (56), Czech Republic (1), Denmark (1), Finland (3), France (7), Germany (24), Greece (13), Hungary (2), India (9), Iran (2), Ireland (2), Israel (4), Italy (41), Japan (47), Kuwait (2), Mexico (1), Netherlands (7), New Zealand (2), Norway (1), Poland (3), Portugal (5), Romania (1), Saudi Arabia (1), Serbia (2), Singapore (4), South Korea (27), Spain (10), Sweden (5), Switzerland (2), Syria (1), Thailand (1), Turkey (6), United Kingdom (15), and United States (95).

### EDITORS-IN-CHIEF

Wasaburo Koizumi, *Kanagawa*  
Hsin-Chen Lee, *Taipei*  
Dimitrios H Roukos, *Ioannina*

### STRATEGY ASSOCIATE

#### EDITORS-IN-CHIEF

Jian-Yuan Chai, *Long Beach*  
Antonio Macrì, *Messina*  
Markus Kurt Menges, *Schwaebisch Hall*

### GUEST EDITORIAL BOARD MEMBERS

Da-Tian Bau, *Taichung*  
Jui-I Chao, *Hsinchu*  
Chiao-Yun Chen, *Kaohsiung*  
Joanne Jeou-Yuan Chen, *Taipei*  
Shih-Hwa Chiou, *Taipei*  
Tzeon-Jye Chiou, *Taipei*  
Jing-Gung Chung, *Taichung*  
Yih-Gang Goan, *Kaohsiung*  
Li-Sung Hsu, *Taichung*  
Tsann-Long Hwang, *Taipei*  
Long-Bin Jeng, *Taichung*  
Kwang-Huei Lin, *Taoyuan*  
Joseph T Tseng, *Tainan*  
Jaw Yuan Wang, *Kaohsiung*  
Tzu-Chen Yen, *Taoyuan*

### MEMBERS OF THE EDITORIAL BOARD



#### Argentina

María Eugenia Pasqualini, *Córdoba*  
Lydia Inés Puricelli, *Buenos Aires*



#### Australia

Ned Abraham, *NSW*

Stephen John Clarke, *NSW*  
Michael Gnant, *Vienna*  
Michael McGuckin, *South Brisbane*  
Muhammed Ashraf Memon, *Queensland*  
Liang Qiao, *NSW*  
Rodney John Scott, *NSW*  
Joanne Patricia Young, *Herston Q*  
Xue-Qin Yu, *NSW*  
Xu Dong Zhang, *NSW*



#### Belgium

Wim Peter Ceelen, *Ghent*  
Van Cutsem Eric, *Leuven*  
Suriano Gianpaolo, *Brussels*  
Xavier Sagaert, *Leuven*  
Jan B Vermorken, *Edegem*



#### Brazil

Raul Angelo Balbinotti, *Caxias do Sul*  
Sonia Maria Olinari, *Colombo*



#### Canada

Alan Graham Casson, *Saskatoon*  
Hans Tse-Kan Chung, *Toronto*  
Rami Kotb, *Sherbrooke*  
Sai Yi Pan, *Ottawa*



#### Chile

Alejandro Hernan Corvalan, *Santiago*  
Juan Carlos Roa, *Temuco*



#### China

Dong Chang, *Beijing*  
George G Chen, *Hong Kong*  
Yong-Chang Chen, *Zhenjiang*  
Chi-Hin Cho, *Hong Kong*  
Ming-Xu Da, *Lanzhou*  
Xiang-Wu Ding, *Xiangfan*  
Yan-Qing Ding, *Guangzhou*  
Bi Feng, *Chengdu*  
Jin Gu, *Beijing*  
Qin-Long Gu, *Shanghai*  
Hai-Tao Guan, *Xi'an*  
Chun-Yi Hao, *Beijing*  
Yu-Tong He, *Shijiazhuang*  
Jian-Kun Hu, *Chengdu*  
Huang-Xian Ju, *Nanjing*  
Wai-Lun Law, *Hong Kong*  
Ming-Yu Li, *Lanzhou*  
Shao Li, *Beijing*  
Ka-Ho Lok, *Hong Kong*  
Maria Li Lung, *Hong Kong*  
Simon Ng, *Hong Kong*  
Wei-Hao Sun, *Nanjing*  
Qian Tao, *Hong Kong*  
Bin Wang, *Nanjing*  
Chun-You Wang, *Wuhan*  
Kai-Juan Wang, *Zhengzhou*  
Wei-Hong Wang, *Beijing*  
Ya-Ping Wang, *Nanjing*  
Ai-Wen Wu, *Beijing*  
Zhao-Lin Xia, *Shanghai*  
Xue-Yuan Xiao, *Beijing*  
Dong Xie, *Shanghai*  
Guo-Qiang Xu, *Hangzhou*  
Yi-Zhuang Xu, *Beijing*  
Winnie Yeo, *Hong Kong*  
Ying-Yan Yu, *Shanghai*

Siu Tsan Yuen, *Hong Kong*  
 Wei-Hui Zhang, *Harbin*  
 Li Zhou, *Beijing*  
 Yong-Ning Zhou, *Lanzhou*



#### Czech Republic

Ondrej Slaby, *Brno*



#### Denmark

Hans Jørgen Nielsen, *Hvidovre*



#### Finland

Riyad Bendardaf, *Turku*  
 Pentti Ilmari Sipponen, *Espoo*  
 Markku Voutilainen, *Jyväskylä*



#### France

Bouvier Anne-Marie, *Cedex*  
 Stéphane Benoist, *Boulogne*  
 Ouaisi Mehdi, *Marseille*  
 Jean-François Rey, *Jean-François Rey*  
 Karem Slim, *Clermont-Ferrand*  
 David Tougeron, *Poitiers*  
 Isabelle Van Seuning, *Lille*



#### Germany

Hajri Amor, *Freiburg*  
 Han-Xiang An, *Marburg*  
 Karl-Friedrich Becker, *München*  
 Stefan Boeck, *Munich*  
 Dietrich Doll, *Marburg*  
 Joachim Drevs, *Freiburg*  
 Volker Ellenrieder, *Marburg*  
 Ines Gütgemann, *Bonn*  
 Jakob Robert Izbicki, *Hamburg*  
 Gisela Keller, *München*  
 Jörg H Kleeff, *Munich*  
 Axel Kleespies, *Munich*  
 Hans-Joachim Meyer, *Solingen*  
 Lars Mueller, *Kiel*  
 Martina Müller-Schilling, *Heidelberg*  
 Joachim Pfannschmidt, *Heidelberg*  
 Marc André Reymond, *Bielefeld*  
 Robert Rosenberg, *München*  
 Ralph Schneider, *Marburg*  
 Helmut K Seitz, *Heidelberg*  
 Nikolas Hendrik Stoecklein, *Düsseldorf*  
 Oliver Stoeltzing, *Mainz*  
 Ludwig G Strauss, *Heidelberg*



#### Greece

Ekaterini Chatzaki, *Alexandroupolis*  
 Elco de Bree, *Heraklion*  
 Maria Gazouli, *Athens*  
 Vassilis Georgoulas, *Heraklion*  
 John Griniatsos, *Athens*  
 Ioannis D Kanellos, *Thessaloniki*  
 Vaios Karanikas, *Larissa*  
 Georgios Koukourakis, *Athens*

Michael I Koukourakis, *Alexandroupolis*  
 Gregory Kouraklis, *Athens*  
 Kostas Syrigos, *Athens*  
 Ioannis A Voutsadakis, *Larissa*



#### Hungary

László Herszényi, *Budapest*  
 Zsuzsa Schaff, *Budapest*



#### India

Uday Chand Ghoshal, *Lucknow*  
 Ruchika Gupta, *New Delhi*  
 Kalpesh Jani, *Vadodara*  
 Ashwani Koul, *Chandigarh*  
 Balraj Mittal, *Lucknow*  
 Rama Devi Mittal, *Lucknow*  
 Susanta Roychoudhury, *Kolkata*  
 Yogeshwer Shukla, *Lucknow*  
 Imtiaz Ahmed Wani, *Kashmir*



#### Iran

Reza Malekzadeh, *Tehran*  
 Mohamad Amin Pourhoseingholi, *Tehran*



#### Ireland

Aileen Maria Houston, *Cork*  
 Colm Ó'Moráin, *Dublin*



#### Israel

Nadir Arber, *Tel Aviv*  
 Eytan Domany, *Rehovot*  
 Dan David Herskho, *Haifa*  
 Yaron Niv, *Patch Tikva*



#### Italy

Massimo Aglietta, *Turin*  
 Domenico Alvaro, *Rome*  
 Azzariti Amalia, *Bari*  
 Marco Braga, *Milan*  
 Federico Cappuzzo, *Rozzano*  
 Lorenzo Capussotti, *Torino*  
 Fabio Carboni, *Rome*  
 Vincenzo Cardinale, *Rome*  
 Luigi Cavanna, *Piacenza*  
 Massimo Colombo, *Milan*  
 Valli De Re, *Pordenone*  
 Ferdinando De Vita, *Naples*  
 Riccardo Dolcetti, *Aviano*  
 Pier Francesco Ferrucci, *Milano*  
 Francesco Fiorica, *Ferrara*  
 Gennaro Galizia, *Naples*  
 Silvano Gallus, *Milano*  
 Milena Gusella, *Trecenta*  
 Carlo La Vecchia, *Milano*  
 Roberto Francesco Labianca, *Bergamo*  
 Massimo Libra, *Catania*  
 Roberto Manfredi, *Bologna*  
 Gabriele Masselli, *Viale del Policlinico*  
 Simone Mocellin, *Padova*

Gianni Mura, *Arezzo*  
 Gerardo Nardone, *Napoli*  
 Gabriella Nesi, *Florence*  
 Francesco Perri, *San Giovanni Rotondo*  
 Francesco Recchia, *Avezzano*  
 Vittorio Ricci, *Pavia*  
 Fabrizio Romano, *Monza*  
 Antonio Russo, *Palermo*  
 Daniele Santini, *Rome*  
 Claudio Sorio, *Verona*  
 Cosimo Sperti, *Padova*  
 Gianni Testino, *Genova*  
 Giuseppe Tonini, *Rome*  
 Bruno Vincenzi, *Rome*  
 Zoli Wainer, *Forlì*  
 Angelo Zullo, *Rome*



#### Japan

Suminori Akiba, *Kagoshima*  
 Keishiro Aoyagi, *Kurume*  
 Narikazu Boku, *Shizuoka*  
 Yataro Daigo, *Tokyo*  
 Itaru Endo, *Yokohama*  
 Mitsuhiro Fujishiro, *Tokyo*  
 Osamu Handa, *Kyoto*  
 Kenji Hibi, *Yokohama*  
 Asahi Hishida, *Nagoya*  
 Eiso Hiyama, *Hiroshima*  
 Atsushi Imagawa, *Okayama*  
 Johji Inazawa, *Tokyo*  
 Terumi Kamisawa, *Tokyo*  
 Tatsuo Kanda, *Niigata*  
 Masaru Katoh, *Tokyo*  
 Takayoshi Kiba, *Hyogo*  
 Hajime Kubo, *Kyoto*  
 Hiroki Kuniyasu, *Kashiwara*  
 Yukinori Kurokawa, *Osaka*  
 Chihaya Maesawa, *Morioka*  
 Yoshinori Marunaka, *Kyoto*  
 Osam Mazda, *Kyoto*  
 Shinichi Miyagawa, *Matsumoto*  
 Eiji Miyoshi, *Suita*  
 Toshiyuki Nakayama, *Nagasaki*  
 Masahiko Nishiyama, *Saitama*  
 Koji Oba, *Kyoto*  
 Masayuki Ohtsuka, *Chiba*  
 Masao Seto, *Aichi*  
 Tomoyuki Shibata, *Aichi*  
 Mitsugi Shimoda, *Tochigi*  
 Haruhiko Sugimura, *Hamamatsu*  
 Tomomitsu Tahara, *Aichi*  
 Shinji Takai, *Osaka*  
 Satoru Takayama, *Nagoya*  
 Akio Tomoda, *Tokyo*  
 Akihiko Tsuchida, *Tokyo*  
 Yasuo Tsuchiya, *Niigata*  
 Takuya Watanabe, *Niigata*  
 Toshiaki Watanabe, *Tokyo*  
 Yo-ichi Yamashita, *Hiroshima*  
 Hiroki Yamaue, *Wakayama*  
 Hiroshi Yasuda, *Kanagawa*  
 Hiroshi Yokomizo, *Kumamoto*  
 Yutaka Yonemura, *Osaka*  
 Reigetsu Yoshikawa, *Hyogo*



#### Kuwait

Fahd Al-Mulla, *Safat*

Salem Alshemmari, *Safat*



#### **Mexico**

Oscar G Arrieta Rodriguez, *Mexico City*



#### **Netherlands**

Jan Paul De Boer, *Amsterdam*

Bloemena Elisabeth, *Bloemena Elisabeth*

Peter JK Kuppen, *Leiden*

Gerrit Albert Meijer, *Amsterdam*

Anyan N Milne, *Utrecht*

Godefridus J Peters, *Amsterdam*

Cornelis FM Sier, *Leiden*



#### **New Zealand**

Lynnette Robin Ferguson, *Auckland*

Jonathan Barnes Koea, *Auckland*



#### **Norway**

Kjetil Søreide, *Stavanger*



#### **Poland**

Andrzej Szkaradkiewicz, *Poznan*

Michal Tenderenda, *Polskiego*

Jerzy Wydmański, *Gliwice*



#### **Portugal**

Maria de Fátima Moutinho Gärtner, *Porto*

Celso Albuquerque Reis, *Porto*

Lucio Lara Santos, *Porto*

Maria Raquel Campos Seruca, *Porto*

Manuel António Rodrigues Teixeira, *Porto*



#### **Romania**

Marius Raica, *Timisoara*



#### **Saudi Arabia**

Ragab Hani Donkol, *Abha*



#### **Serbia**

Milos M Bjelovic, *Belgrade*

Goran Zoran Stanojevic, *Nis*



#### **Singapore**

Peh Yean Cheah, *Singapore*

Si-Shen Feng, *Singapore*

Zhi-Wei Huang, *Singapore*

Qi Zeng, *Singapore*



#### **South Korea**

Seungmin Bang, *Seoul*

Daeho Cho, *Seoul*

Byung Ihn Choi, *Seoul*

Hyun Cheol Chung, *Seoul*

Sang-Uk Han, *Suwon*

Jun-Hyeog Jang, *Incheon*

Seong Woo Jeon, *Daegu*

Dae Hwan Kang, *Mulgeum-Gigu*

Gyeong Hoon Kang, *Seoul*

Dong Yi Kim, *Gwangju*

Jae J Kim, *Seoul*

Jin Cheon Kim, *Seoul*

Jong Gwang Kim, *Daegu*

Min Chan Kim, *Busan*

Samyong Kim, *Daejeon*

Inchul Lee, *Seoul*

Jung Weon Lee, *Seoul*

Kyu Taek Lee, *Seoul*

Kyung Hee Lee, *Daegu*

Na Gyong Lee, *Seoul*

Suk Kyeong Lee, *Seoul*

Jong-Baeck Lim, *Seoul*

Young Joo Min, *Ulsan*

Sung-Soo Park, *Seoul*

Young Kee Shin, *Seoul*

Hee Jung Son, *Seoul*

Si Young Song, *Seoul*



#### **Spain**

Manuel Benito, *Madrid*

Ignacio Casal, *Madrid*

Antoni Castells, *Barcelona*

Jose JG Marin, *Salamanca*

Joan Maurel, *Barcelona*

Emma Folch Puy, *Barcelona*

Jose Manuel Ramia, *Guadalajara*

Margarita Sanchez-Beato, *Madrid*

Laura Valle, *Barcelona*

Jesus Vioque, *San Juan*



#### **Sweden**

Nils Albiin, *Stockholm*

Samuel Lundin, *Göteborg*

Haile Mahteme, *Uppsala*

Richard Palmqvist, *Umea*

Ning Xu, *Lund*



#### **Switzerland**

Paul M Schneider, *Zurich*

Luigi Tornillo, *Basel*



#### **Syria**

Zuhir Alshehabi, *Lattakia*



#### **Thailand**

Sopit Wongkham, *Khon Kaen*



#### **Turkey**

Uğur Coşkun, *Ankara*

Sukru Mehmet Erturk, *Istanbul*

Vedat Goral, *Diyarbakir*

Yavuz Selim Sari, *Istanbul*

Mesut Tez, *Ankara*

Murat H Yener, *Istanbul*



#### **United Kingdom**

Shrikant Anant, *Oklahoma City*

Runjan Chetty, *Scotland*

Chris Deans, *Edinburgh*

Dipok Kumar Dhar, *London*

Thomas Ronald Jeffry Evans, *Glasgow*

Giuseppe Garcea, *Leicester*

Oleg Gerasimenko, *Liverpool*

Neena Kalia, *Birmingham*

Anthony Maraveyas, *East Yorkshire*

Andrew Maw, *North Wales*

Kymberley Thorne, *Swansea*

Chris Tselepis, *Birmingham*

Nicholas Francis Scot Watson, *Nottingham*

Ling-Sen Wong, *Coventry*

Lu-Gang Yu, *Liverpool*



#### **United States**

Mohammad Reza Abbaszadegan, *Phoenix*

Gianfranco Alpini, *Temple*

Seung Joon Baek, *Knoxville*

Jamie S Barkin, *Miami Beach*

Carol Bernstein, *Arizona*

Paolo Boffetta, *New York*

Kimberly Maureen Brown, *Kansas City*

De-Liang Cao, *Springfield*

Weibiao Cao, *Providence*

Chris N Conteas, *Los Angeles*

Pelayo Correa, *Nashville*

Joseph John Cullen, *JCP*

James Campbell Cusack, *Boston*

Ananya Das, *Scottsdale*

Juan Dominguez-Bendala, *Miami*

Wafik S El-Deiry, *Philadelphia*

Laura Elnitski, *Rockville*

Guy Douglas Eslick, *Boston*

Thomas Joseph Fahey III, *New York*

James W Freeman, *San Antonio*

Bruce Joseph Giantonio, *Philadelphia*

Ajay Goel, *Dallas*

Karen Gould, *Omaha*

Nagana Gowda A Gowda, *West Lafayette*

Stephen Randolph Grobmyer, *Florida*

Young S Hahn, *Charlottesville*

John W Harmon, *Maryland*

Paul J Higgins, *New York*

Steven Norbit Hochwald, *Gainesville*

Jason L Hornick, *Boston*

Qin Huang, *Duarte*

Su-Yun Huang, *Houston*

Jamal A Ibdah, *Columbia*

Yihong Jiang-Cao Kaufmann, *Little Rock*

Temitope Olubunmilayo Keku, *Chapel Hill*

Saeed Khan, *Silver Spring*

Vijay Pranjivan Khatri, *Sacramento*

Peter Sean Kozuch, *New York*  
 Sunil Krishnan, *Houston*  
 Robert R Langley, *Houston*  
 Feng-Zhi Li, *New York*  
 Otto Schiueh-Tzang Lin, *Seattle*  
 Ke-Bin Liu, *Augusta*  
 Rui-Hai Liu, *Ithaca*  
 Xiang-Dong Liu, *Wilmington*  
 Deryk Thomas Loo, *South San Francisco*  
 Andrew M Lowy, *La Jolla*  
 Bo Lu, *Nashville*  
 David M Lubman, *Ann Arbor*  
 James David Luketich, *Pittsburgh*  
 Ju-Hua Luo, *Morgantown*  
 Henry T Lynch, *Omaha*  
 Shelli R Mcalpine, *San Diego*  
 Ellen Darcy McPhail, *Rochester*  
 Anil Mishra, *Cincinnati*  
 Priyabrata Mukherjee, *Rochester*

Steffan Todd Nawrocki, *San Antonio*  
 Kevin Tri Nguyen, *Pittsburgh*  
 Shuji Ogino, *Boston*  
 Macaulay Onuigbo, *Eau Claire*  
 Jong Park, *Tampa*  
 Philip Agop Philip, *Detriot*  
 Blase N Polite, *Chicago*  
 James Andrew Radosevich, *Chicago*  
 Jasti S Rao, *Peoria*  
 Srinevas Kadumpalli Reddy, *Durham*  
 Raffaniello Robert, *New York*  
 Stephen H Safe, *College Station*  
 Muhammad Wasif Saif, *New Haven*  
 Prateek Sharma, *Kansas City*  
 Eric Tatsuo Shinohara, *Philadelphia*  
 Liviu Andrei Sicinski, *Nashville*  
 William Small Jr, *Chicago*  
 Sanjay K Srivastava, *Amarillo*  
 Gloria H Su, *New York*

Sujha Subramanian, *Waltham*  
 Mitsushige Sugimoto, *Texas*  
 David W Townsend, *Knoxville*  
 Asad Umar, *Rockville*  
 Ji-Ping Wang, *Buffalo*  
 Zheng-He Wang, *Cleveland*  
 Michael J Wargovich, *Charleston*  
 Neal W Wilkinson, *Iowa City*  
 Siu-Fun Wong, *Pomona*  
 Shen-Hong Wu, *New York*  
 Jing-Wu Xie, *Indianapolis*  
 Ke-Ping Xie, *Houston*  
 Hao-Dong Xu, *Rochester*  
 Xiao-Chun Xu, *Houston*  
 Gary Y Yang, *New York*  
 Wan-Cai Yang, *Chicago*  
 Zeng-Quan Yang, *Detroit*  
 Zuo-Feng Zhang, *South Los Angeles*  
 Andrew X Zhu, *Boston*



**REVIEW**

- 186** Primary hepatocellular carcinoma and metabolic syndrome: An update

*Rahman R, Hammoud GM, Almashhrawi AA, Ahmed KT, Ibdah JA*



## Contents

*World Journal of Gastrointestinal Oncology*  
Volume 5 Number 9 September 15, 2013

### APPENDIX

I-V Instructions to authors

### ABOUT COVER

*World J Gastrointest Oncol* Editorial Board, Wei-Hong Wang, Professor, Department of Gastroenterology, First Hospital of Peking University, Xishiku Street, Xicheng District, Beijing 100034, China

### AIM AND SCOPE

*World Journal of Gastrointestinal Oncology* (*World J Gastrointest Oncol*, *WJGO*, online ISSN 1948-5204, DOI: 10.4251) is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

*WJGO* covers topics concerning carcinogenesis, tumorigenesis, metastasis, diagnosis, prevention, prognosis, clinical manifestations, nutritional support, molecular mechanisms, and therapy of benign and malignant tumors of the digestive tract. The current columns of *WJGO* include editorial, frontier, diagnostic advances, therapeutics advances, field of vision, mini-reviews, review, topic highlight, medical ethics, original articles, case report, clinical case conference (Clinicopathological conference), and autobiography. Priority publication will be given to articles concerning diagnosis and treatment of gastrointestinal oncology diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJGO*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great clinical significance.

### INDEXING/ABSTRACTING

*World Journal of Gastrointestinal Oncology* is now indexed in PubMed Central, PubMed, Digital Object Identifier, and Directory of Open Access Journals.

### FLYLEAF

I-IV Editorial Board

### EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xin-Xin Che*  
Responsible Electronic Editor: *Ya-Jing Lu*  
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Xue-Mei Cui*

#### NAME OF JOURNAL

*World Journal of Gastrointestinal Oncology*

#### ISSN

ISSN 1948-5204 (online)

#### LAUNCH DATE

October 15, 2009

#### FREQUENCY

Monthly

#### EDITORS-IN-CHIEF

**Wasaburo Koizumi, MD, PhD, Professor, Chairman**, Department of Gastroenterology, Gastrointestinal Oncology, School of Medicine, Kitasato University, 2-1-1 Asamizodai Minamiku Sagamihara Kanagawa 252-0380, Japan

**Hsin-Chen Lee, PhD, Professor**, Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan

**Dimitrios H Roukos, MD, PhD, Professor, Person-**

alized Cancer Genomic Medicine, Human Cancer Biobank Center, Ioannina University, Metabatiko Ktirio Panepistimiou Ioanninon, Office 229, Ioannina, TK 45110, Greece

#### EDITORIAL OFFICE

Jin-Lei Wang, Director  
Xiu-Xia Song, Vice Director  
*World Journal of Gastrointestinal Oncology*  
Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China  
Telephone: +86-10-85381891  
Fax: +86-10-85381893  
E-mail: [wjgo@wjgnet.com](mailto:wjgo@wjgnet.com)  
<http://www.wjgnet.com>

#### PUBLISHER

Baishideng Publishing Group Co., Limited  
Flat C, 23/F, Lucky Plaza, 315-321 Lockhart Road, Wanchai, Hong Kong, China  
Fax: +852-65557188  
Telephone: +852-31779906  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

#### PUBLICATION DATE

September 15, 2013

#### COPYRIGHT

© 2013 Baishideng. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

#### SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

#### INSTRUCTIONS TO AUTHORS

Full instructions are available online at [http://www.wjgnet.com/2222-0682/g\\_info\\_20100722180909.htm](http://www.wjgnet.com/2222-0682/g_info_20100722180909.htm).

#### ONLINE SUBMISSION

<http://www.wjgnet.com/esps/>

## Primary hepatocellular carcinoma and metabolic syndrome: An update

Rubayat Rahman, Ghassan M Hammoud, Ashraf A Almashhrawi, Khulood T Ahmed, Jamal A Ibdah

Rubayat Rahman, Ghassan M Hammoud, Ashraf A Almashhrawi, Khulood T Ahmed, Jamal A Ibdah, Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO 65212, United States

**Author contributions:** Rahman R wrote and revised the manuscript; Hammoud GM, Almashhrawi AA and Ahmed KT were involved in reviewing the literature and collecting data; Ibdah JA conceived the topic, contributed to the writing, analyzed and edited the manuscript, and provided overall intellectual input into the design and execution of the manuscript.

Supported by Raymond E and Vaona H Peck Chair in Cancer Research

Correspondence to: Jamal A Ibdah, MD, PhD, Professor, Director, Division of Gastroenterology and Hepatology, University of Missouri-Columbia, 319 Jesse Hall, Columbia, MO 65212, United States. [ibdahj@health.missouri.edu](mailto:ibdahj@health.missouri.edu)

Telephone: +1-573-8827349 Fax: +1-573-8844595

Received: May 26, 2013 Revised: August 14, 2013

Accepted: August 20, 2013

Published online: September 15, 2013

ciation with obesity, diabetes mellitus, hyperlipidemia, and hypertension. Current understanding of pathophysiology, clinical features, treatments, outcomes, and surveillance of hepatocellular carcinoma in the background of metabolic syndrome and non-alcoholic fatty liver disease is reviewed. With the current epidemic of metabolic syndrome, the number of patients with non-alcoholic fatty liver disease is increasing. Subsequently, it is expected that the incidence and prevalence of HCC will also increase. It is very important for the scientific community to shed more light on the pathogenesis of HCC with metabolic syndrome, both with and without cirrhosis. At the same time it is also important to quantify the risk of hepatocellular carcinoma associated with the metabolic syndrome in a prospective setting and develop surveillance recommendations for detection of hepatocellular carcinoma in patients with metabolic syndrome.

© 2013 Baishideng. All rights reserved.

**Key words:** Liver; Hepatocellular carcinoma; Metabolic syndrome; Non-alcoholic fatty liver disease; Obesity

### Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. The incidence of hepatocellular carcinoma has increased dramatically by 80% over the past two decades in the United States. Numerous basic science and clinical studies have documented a strong association between hepatocellular carcinoma and the metabolic syndrome. These studies have documented that, in most patients, non-alcoholic fatty liver disease is the hepatic manifestation of the metabolic syndrome, which may progress to hepatocellular carcinoma through the cirrhotic process. However, minority of patients with non-alcoholic fatty liver disease may progress to hepatocellular carcinoma without cirrhosis. This review summarizes the current literature of the link between hepatocellular carcinoma and metabolic syndrome with special emphasis on various components of the metabolic syndrome including risk of asso-

**Core tip:** Hepatocellular carcinoma is a common malignancy with dismal outcome. The metabolic syndrome has been implicated for the recent increase in hepatocellular carcinoma. Numerous studies have shown a strong association between hepatocellular carcinoma and the metabolic syndrome. This review summarizes the current literature linking hepatocellular carcinoma and the metabolic syndrome.

Rahman R, Hammoud GM, Almashhrawi AA, Ahmed KT, Ibdah JA. Primary hepatocellular carcinoma and metabolic syndrome: An update. *World J Gastrointest Oncol* 2013; 5(9): 186-194 Available from: URL: <http://www.wjgnet.com/1948-5204/full/v5/i9/186.htm> DOI: <http://dx.doi.org/10.4251/wjgo.v5.i9.186>



## INTRODUCTION

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy with increasing incidence and prevalence both nationally and internationally that was evident more than a decade ago<sup>[1]</sup>. According to International Agency for Research on Cancer (IARC), HCC has high fatality worldwide with overall ratio of mortality to incidence of 0.93<sup>[2]</sup>. The incidence of HCC has increased dramatically by 80% in the last two decades in the United States<sup>[3]</sup>. This phenomenon was also observed in many of the developed countries of the world<sup>[4]</sup>. The trend of increased incidence of HCC from hepatitis C virus is predicted to plateau by 2020 with no significant changes of other known causes<sup>[5]</sup>. Most of the high risk entities of HCC including hepatitis B virus, hepatitis C virus, and alcohol are well defined. However, 5%-30% of the HCC cases do not have any identifiable risk factor<sup>[6]</sup>. Moreover, some studies have indicated that even up to 50% cases of HCC may not have any readily identifiable risk factor<sup>[7,8]</sup>. The majority of these “cryptogenic” HCC in the United States and many other developed countries are now widely attributed to the metabolic syndrome, specially its hepatic manifestation non-alcoholic fatty liver disease (NAFLD)<sup>[9]</sup>.

Metabolic syndrome (MetS), a cluster of metabolic abnormalities is now considered a major public health issue worldwide. It is particularly important in the developed countries because of the alarming obesity epidemic. MetS is also considered to be the central association of the current epidemic of diabetes and cardiovascular diseases<sup>[10]</sup>. It is estimated that 25% of the United States population meet the diagnostic criteria of MetS<sup>[11]</sup>. According to the Third National Health and Nutrition Examination Survey (NHANES III) criteria, about 47 million people have metabolic syndrome in the United States and the number is increasing at an alarming rate<sup>[12]</sup>. In the background of increasing “cryptogenic” HCC, MetS and NAFLD, it is important to review the relationship between HCC and the MetS.

## EPIDEMIOLOGY OF HCC

Worldwide, HCC is the fifth most common cancer in men and the seventh most common cancer in women according to the IARC. Most of the disease burden of HCC resides in developing countries such as East Asia, South East Asia, and sub-Saharan Africa, where almost 85% of the cases occur. The overall gender ratio of male: female is 2.4. Low incidence rates are estimated in developed countries, with the exception of Southern Europe where the incidence in men is significantly higher than in other developed regions. Worldwide, there was an estimated 694000 deaths from HCC in 2008 (477000 in men, 217000 in women), making it the third most common cause of death from cancer. The geographical distribution of HCC mortality rates is similar to that observed for the incidence rates indicating more or less

similar outcomes across the world<sup>[13]</sup>.

In the United States, the average age of diagnosis for HCC is 63 years (62 years for males, and 69 years for females). The age-adjusted incidence rate is 7.7/100000 per year. The age-adjusted death rate from HCC is 5.5/100000 per year. It is estimated that the median age at death for HCC is 68 years of age. However, gender, race and ethnic disparities exist in the incidence and mortality rates of HCC in the United States. Table 1 summarizes the incidence and mortality rates of HCC according to race, ethnicity and gender based on cases diagnosed in 2006-2010 from 18 Surveillance Epidemiology and End Results (SEER) geographic areas<sup>[14,15]</sup>.

The Centers for Disease Control and Prevention (CDC) examined all HCC cases (48596) diagnosed during 2001-2006 that were reported to the National Program of Cancer Registries (NPCR) or SEER from 45 cancer registries (covering 90.4% of the United States population). As shown in Table 2<sup>[16]</sup>, the data document that the incidence rate of HCC is on the rise in both genders. During this period, the annual percentage change (APC) for males (3.6%) was significantly higher than the APC for females (2.3%). The largest significant increase in HCC incidence rates were among Non-Hispanic Whites (APC = 3.8%), African American (APC = 4.8%), and persons aged 50-59 years (APC = 9.1%)<sup>[16]</sup>.

## METABOLIC SYNDROME

The World Health Organization (WHO) was the first to identify MetS as a global problem and took initiative to propose a definition and diagnostic criteria. The WHO used insulin resistance (IR) as the major criteria for defining the MetS. However, in clinical practice it was difficult to quantify or qualify insulin resistance across the world<sup>[17]</sup>. Subsequently in 2001, the National Cholesterol Education Program expert panel on the detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III or ATP III) defined the metabolic syndrome by the presence of three parameters of the following criteria: hyperglycemia, hypertriglyceridemia, low HDL, abdominal obesity and hypertension<sup>[18]</sup>. Recently, the International Diabetes Federation (IDF) adopted a definition with emphasis on central obesity in MetS such that central obesity plus two additional factors are required in order to diagnose the MetS<sup>[19]</sup>. Table 3 summarizes the criteria used to define the metabolic syndrome over time.

The prevalence of MetS varies worldwide depending on the geographic location, socioeconomic background, culture and ethnicity. It is estimated that the prevalence of MetS is about 14% in China, 26% in South Asia, 19% in Australia, 9% in France and 18% in Italy. Although prevalence of obesity as defined by the WHO is relatively low in Asia compared to western countries, metabolic syndrome is growing into a significant public health problem. Comparative studies indicate that metabolic

**Table 1** Incidence and mortality rates of hepatocellular carcinoma according to race/ethnicity and gender, reported in Surveillance Epidemiology and End Results database 2006-2010

Race/Ethnicity	Incidence rate per 100000		Mortality rate per 100000	
	Male	Female	Male	Female
All races	11.9	4.0	8.3	3.4
Non-Hispanic White	10.4	3.5	7.6	3.2
African American	15.1	4.5	11.8	4.1
Hispanics	18.3	6.9	12.3	5.4
Asian/Pacific Islander	21.4	8.2	14.4	6.0
American Indian/Alaska Native	20.6	7.7	13.2	6.1

responses to obesity may be greater in South and East Asians than their western counterparts at given body mass indexes (BMI)<sup>[10,20]</sup>.

The prevalence of MetS was evaluated in adults in the United States participating in the third National Health and Nutrition Examination Survey (NHANES III, 1988 to 1994). The overall prevalence was 22%, with an age-dependent increase (6.7, 43.5, and 42.0% for ages 20 to 29, 60 to 69, and > 70 years, respectively)<sup>[12]</sup>. Data from NHANES 1999 to 2000 demonstrate that the prevalence has continued to increase, particularly in women. The unrelenting increase in the prevalence of obesity in the United States suggests that the current prevalence of the metabolic syndrome is now very likely higher than that estimated from 1988-1994 NHANES III data<sup>[11]</sup>. According to CDC in 2008, the obesity rate among adult Americans was estimated at 32.2% for men and 35.5% for women; these rates were roughly confirmed again for 2009-2010. Recent data indicate that 34% of the adult in the United States met the criteria for MetS and the rate of increment was equal in both sexes<sup>[21]</sup>. This rapidly increasing prevalence of obesity among adults in the United States will lead to even higher rates of the MetS now and in the near future<sup>[22]</sup>. Study has shown that susceptibility to obesity cannot simply be attributed to the combination of genetic and environmental factors, but can also be triggered by influences on a baby's development during intrauterine period, including mother's dietary habit. A mother's nutrition while pregnant can cause important epigenetic changes that contribute to her offspring's risk of obesity during childhood<sup>[23]</sup>.

## HEPATOCELLULAR CARCINOMA AND THE METABOLIC SYNDROME

HCC is one of the most common malignancies in the world, with more than 500000 new cases per year<sup>[24]</sup>. Data from SEER which covers 28% of the United States population, reported a total of 4032 cases of HCC in 2001. This number increased by 27% to 5122 in 2005 and by 60% to 6464 in 2009<sup>[14]</sup>. It is predicted that the total number of HCC will continue to increase in the future<sup>[25]</sup>. Since the association is not readily identifiable in a significant percentage of HCC cases, it was postulated,

**Table 2** Changes in incidence rate of hepatocellular carcinoma from 2001 to 2006

Incidence rate/100000	2001	2006
Overall	2.7	3.2
Male	4.5	5.4
Female	1.2	1.4

and now well established, that the MetS is contributing to the development of HCC. With the current rising epidemic of obesity and MetS in the general population, it is established that MetS is responsible for HCC cases with unaccounted association<sup>[26]</sup>. The prevalence of MetS is paralleling the epidemic of obesity in the United States. Obesity and MetS are well documented risks factors associated with NAFLD, a metabolic hepatic disorder that can progress to nonalcoholic steatohepatitis (NASH) and fibrosis. A subset of aggressive NAFLD can lead to cirrhosis and HCC. Worldwide, it is estimated that there are 400 million obese individuals, among whom 75% have NAFLD. Up to 20% have NASH and over 5-10 years, 33% of whom will develop cirrhosis<sup>[27,28]</sup>. In another study, among patients with NAFLD followed for a mean of 8 years, the occurrence of cirrhosis was 20% and the incidence of HCC was 1%<sup>[29]</sup>. It is estimated that the prevalence of NAFLD is 3-10 times higher than the prevalence of hepatitis C virus (HCV) in the United States ranging from 5.5% to 31%<sup>[30,31]</sup>. Besides being the most rapidly increasing cause of cancer death in the United States, the economic burden of HCC is also enormous with an estimated cost of more than 437 million dollars per year<sup>[32]</sup>. It is very imperative for the medical care providers to appreciate the association of MetS and HCC with appropriate surveillance for the high risk population groups.

## HEPATOCELLULAR CARCINOMA RISK FACTORS ASSOCIATED WITH THE METABOLIC SYNDROME

### Obesity

Many malignancies have been directly or indirectly associated with obesity and HCC is among these established malignancies<sup>[33,34]</sup>. Meta-analysis of 11 studies conducted in United States, Europe and Asia demonstrated that both overweight (RR = 1.07, 95%CI: 1.01-1.15) and obesity (RR = 1.85, 95%CI: 1.44-2.37) were associated with development of HCC<sup>[35]</sup>. Even in patients with chronic HBV and HCV, coexisting obesity has been associated with increased risk for HCC by more than 100-fold<sup>[36]</sup>. A Large prospective trial showed that obesity has influenced disease progression, and increased weight is associated with overall cancer mortality. In a prospective study of United States adults, BMI > 35 kg/m<sup>2</sup> negatively impacted overall mortality from HCC with a relative risk (RR) of 1.68 times in women and 4.52 times in men. This was the highest for any malignancy analyzed

**Table 3** Criteria used to define the metabolic syndrome

Diagnostic criterion	WHO (1999)	ATP (2005)	IDF (2006)
Abdominal obesity	BMI - Waist/hip ratio > 0.9 (men) or > 0.85 (women) or BMI $\geq$ 30 kg/m <sup>2</sup>	Central - Waist $\geq$ 102 cm (men) or $\geq$ 88 cm (women)	Central - Waist $\geq$ 102 cm (men) or $\geq$ 88 cm (women)
Hypertension	$\geq$ 140/90 mmHg	$\geq$ 130/85 mmHg or drug treatment for hypertension	$\geq$ 130/85 mmHg or drug treatment for hypertension
Fasting glucose	IPG/HOMA	$\geq$ 5.6 mol/L	$\geq$ 6.1 mol/L
Hypertriglyceridemia	$\geq$ 1.7 mmol/L (150 mg/dL) or drug treatment for elevated triglycerides	$\geq$ 1.7 mmol/L (150 mg/dL) or drug treatment for elevated triglycerides	$\geq$ 1.7 mmol/L (150 mg/dL) or drug treatment for elevated triglycerides
Low HDL cholesterol	Not used	< 1.0 mmol/L (40 mg/dL) (men); < 1.3 mmol/L (50 mg/dL) (women) or drug treatment for low HDL	< 1.0 mmol/L (40 mg/dL) (men); < 1.3 mmol/L (50 mg/dL) (women) or drug treatment for low HDL
Micro albuminuria	Used	Not used	Not used

ATP: Adult Treatment Panel; BMI: Body mass index; HDL: High-density lipoprotein; IDF: International Diabetes Federation; IPG/HOMA: Impaired plasma glucose/homeostatic model assessment; WHO: World Health Organization.

in the study<sup>[37]</sup>. Comparable conclusions were drawn in both Danish and Korean studies analyzing large cohorts of obese patients<sup>[38,39]</sup>. SEER-Medicare data analysis from 1993 to 2005 showed that adjusted odd ratio (OR) of obesity for HCC was 1.93 (95%CI: 1.71-2.18,  $P < 0.0001$ )<sup>[40]</sup>. The Metabolic Syndrome and Cancer Project (Me-Can) from Norway, Sweden and Austria examining 578700 subjects showed RR of 1.39 (95%CI: 1.24-1.58) for obesity in the development of HCC<sup>[25]</sup>. Obesity is also an independent predictor of HCC in obese transplanted patients (4% *vs* 3.4%)<sup>[34]</sup>.

Moreover, in a large retrospective cohort of 342 consecutive patients who underwent liver transplantation for hepatocellular carcinoma, BMI was found to be an independent predictor of micro vascular invasion<sup>[41]</sup>. Nonetheless, review of the United Network of Organ Sharing database on all liver transplantations performed in the United States, showed that obesity was an independent predictor of HCC in patients with alcoholic cirrhosis and cryptogenic cirrhosis, but not for those with cirrhosis of other associations<sup>[34]</sup>.

### Diabetes mellitus

Diabetes mellitus (DM) is an independent risk factor for the development of HCC. Analysis of 2061 patients with HCC showed a significant increase in the development of HCC (OR 2.87, 95%CI: 2.49-3.3) in the background of DM regardless of the presence of other risk factors. There was a significant positive interaction between obesity and HCV ( $P < 0.0001$ ) for HCC<sup>[42]</sup>. Multiple European studies showed RR of 4.5 of HCC in male patients, with a lower, but still significant RR of 1.86 in female patients with DM<sup>[43-45]</sup>. Moreover, a large longitudinal study analyzing 173643 DM and 650620 non-DM controls over a period of 10- to 15-year revealed a RR of 2. This risk estimation even persisted after exclusion of the patients with viral hepatitis, alcohol use, or fatty liver disease<sup>[46]</sup>. DM was established as an independent risk factor for the development of HCC in 12 cohort studies after adjustment for infectious and alcoholic associations<sup>[47]</sup>. In a large population based study

with 615532 DM patients and 614871 controls, the overall hazard rate for the development of HCC in males and females was 32.76 and 17.41 per 10000 patients-years, respectively. Furthermore, in a recent Italian case-control study including 185 HCC cases and 404 controls, diabetes and obesity were positively associated with HCC risk, with ORs of 4.33 (95%CI: 1.89-9.86) and 1.97 (95%CI: 1.03-3.79), respectively<sup>[48]</sup>. DM with cirrhosis demonstrated the highest risk of HCC development (RR = 82.25, 95%CI: 76.84-94.58)<sup>[49]</sup>. SEER-Medicare data analysis from 1993 to 2005 showed that adjusted OR of DM for HCC was 2.9 (95%CI: 2.71-3.1,  $P < 0.0001$ )<sup>[40]</sup>. The Me-Can from Norway, Sweden and Austria examining 578700 subjects showed RR of 2.13 (95%CI: 1.55-2.94) for DM in the development of HCC<sup>[25]</sup>.

### Hyperlipidemia

Hyperlipidemia is an integral part of the MetS. Although there have been several studies examining the association of HCC with MetS, only few studies reported the association of HCC with hyperlipidemia individually. Hyperlipidemia, in many instances is closely related with the central mechanism of insulin resistance in MetS. SEER-Medicare data analysis from 1993 to 2005 showed that adjusted OR of dyslipoproteinemia for HCC was 1.35 (95%CI: 1.26-2.45,  $P < 0.0001$ )<sup>[40]</sup>. The Me-Can from Norway, Sweden and Austria examining 578700 subjects showed RR of 0.85 (95%CI: 0.65-1.10) in the development of HCC<sup>[25]</sup>. Although not well understood, this discrepancy between Me-Can study<sup>[25]</sup> and SEER-Medicare data analysis<sup>[40]</sup> could be secondary to the short follow up period in the Me-Can study.


### Hypertension

Similar to hyperlipidemia, hypertension is one of the parameters of the metabolic syndrome. Very few studies examined the individual association of HCC with hypertension. SEER-Medicare data analysis from 1993 to 2005 showed that adjusted OR of hypertension for HCC was 2.22 (95%CI: 2.04-2.42,  $P < 0.0001$ )<sup>[40]</sup>. In a study from

**Table 4 Association of different components of metabolic syndrome and the development of hepatocellular carcinoma**

Author	Type of Study	Risk Parameter	Obesity	DM	Hyperlipidemia	HTN
Larsson <i>et al</i> <sup>[35]</sup>	Meta analysis	RR	1.85			
Calle <i>et al</i> <sup>[37]</sup>	Prospective	RR	4.52 (Male) 1.68 (Female)			
Welzel <i>et al</i> <sup>[40]</sup>	Retrospective	OR	1.93	2.9	1.35	2.2
Borena <i>et al</i> <sup>[25]</sup>	Prospective	RR	1.39	2.13	0.85	2.08
Turati <i>et al</i> <sup>[48]</sup>	Retrospective	OR	1.97	4.33		
Davila <i>et al</i> <sup>[42]</sup>	Retrospective	OR		2.87		
Lagiou <i>et al</i> <sup>[43]</sup>	Prospective	RR		4.5 (Male) 1.86 (Female)		
El-Serag <i>et al</i> <sup>[46]</sup>	Prospective	RR		2		
Tomimaru <i>et al</i> <sup>[55]</sup>	Prospective	RR		82.2 (with cirrhosis)		

RR: Relative risk; OR: Odd ratio; DM: Diabetes mellitus; HTN: Hypertension.



**Figure 1 Pathogenesis of hepatocellular carcinoma in the background of metabolic syndrome.** PPAR: Peroxisome proliferator-activated receptors; NASH: Nonalcoholic steatohepatitis; FFA: Free fatty acid; IRS-1: Insulin receptor substrate 1; TNF- $\alpha$ : Tumor necrosis factor  $\alpha$ .

a single center, among 209 NBNC-HCC patients, 38% had hypertension, and 11% had hyperlipidemia<sup>[50]</sup>. The Me-Can from Norway, Sweden and Austria examining 578700 subjects showed RR of 2.08 (95%CI: 0.95-4.73) for hypertension in the development of HCC<sup>[25]</sup>.

## PATHOPHYSIOLOGY OF HEPATOCELLULAR CARCINOMA ASSOCIATED WITH THE METABOLIC SYNDROME

Hepatocellular carcinoma generally arises in the background of cirrhosis (Figure 1). Factors that are associated with development of the metabolic syndrome and HCC maybe inherently linked (Table 4). It is well postulated and established that insulin resistance is the principal dominator that links all the components of MetS. Insulin resistance exerts a major role in the development of NAFLD even in lean subjects with appropriate glycemic control<sup>[51]</sup>. Insulin resistance leads to fat accumulation in the hepatocytes by lipolysis and hyperinsulinemia. Aberrant adipose tissue accumulation, release of pro-inflammatory

cytokines, inhibition of anti-inflammatory cytokines and lipotoxicity collectively promote and propagate both systemic and hepatic insulin resistance, leading to hyperinsulinemia<sup>[52]</sup>. Multiple mechanisms have been proposed that may work simultaneously and complementary to each other to provide a tumor promoting environment in MetS. This may distinguish the pathogenesis of HCC related to NAFLD from that of infectious and alcoholic associations<sup>[53,54]</sup>. Hyperinsulinemia results in increased insulin growth factor-1 (IGF-1) which has important proliferative and antiapoptotic effects. IGF-1 promotes angiogenesis through increased vascular endothelial growth factor production, which in turn leads to cancer cell proliferation. Upregulation in IGF-1/IRS1 pathway has been shown to contribute to the pathogenesis of HCC<sup>[55]</sup>. Likewise, peroxisome proliferator-activated receptors (PPARs) regulate a network of genes encoding protein involved in fatty acids uptake, enzymes required for the  $\beta$ -oxidation of fatty acids, and enzymes required for ketogenesis. PPARs play an important role in fatty liver, and its involvement in carcinogenesis has been clarified. Abnormal stimulation of PPAR- $\alpha$  has been shown to induce HCC in animal models<sup>[56]</sup>.

Expansion of adipose tissue in obesity may lead to release of pro-inflammatory cytokines. Visceral fat accumulation has been shown to be an independent risk factor for HCC recurrence after curative treatment<sup>[57]</sup>. Further, Interleukin-6 (IL-6) has been linked to obesity-associated inflammatory response such that it activates STAT3 potentiating cell proliferation and anti-apoptotic mechanisms. Tumor necrosis factor (TNF) activates pro-oncogenic pathways including JNK, NF- $\kappa$ B, mTOR, and the extracellular signal-regulated kinases<sup>[58,59]</sup>. In experimental models, both TNF and IL-6 strongly promote HCC growth induced by diethyl nitrosamine in mice. Both dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression<sup>[60]</sup>.

Adiponectin (an anti-inflammatory cytokine) is expressed at reduced levels in MetS and NAFLD, which may not sufficient to suppress endotoxin-mediated inflammatory signaling. On the other hand, high circulating levels of leptin in NAFLD exert pro-inflammatory



and pro-fibrogenic effects in NAFLD<sup>[61-63]</sup>. In addition, there is evidence that lipid peroxides and free radicals are elevated in MetS, which may cause oxidative injury, endoplasmic reticulum stress, mitochondrial dysfunction, and apoptosis<sup>[64]</sup>.

## CLINICAL FEATURES OF HCC IN THE BACKGROUND OF METABOLIC SYNDROME

NAFLD leading to cirrhosis can predispose to HCC. There are several reports that patients may even develop HCC from steatosis without cirrhosis. However, the degree of developing HCC from NAFLD is less in comparison to infectious and alcoholic associations<sup>[65]</sup>. Patients who develop HCC in the background of MetS are predominantly males. The average age of diagnosis is older than HCC secondary to other causes; and HCC secondary to NAFLD is generally well differentiated with early stages at diagnosis<sup>[53]</sup>. An analysis of 87 Japanese patients with HCC in the background of MetS showed a median age of 72 years, and the male patients appear to develop HCC at a less-advanced stage of liver fibrosis<sup>[66]</sup>. Similar results were also confirmed by another Japanese study<sup>[67]</sup>. Male predominance, older age at diagnosis, and early stages were also found in a prospective study comparing 34 NASH cases with HCC with 348 NASH patients without HCC<sup>[68]</sup>. A recent study from China examined 169 patients with NAFLD associated HCC. The result showed 73% male predominance with average age of diagnosis of 67 years, 99% had at least one component of MetS, 76% with solitary nodule (mean 3.4 cm) and most of the patients were well or moderately differentiated. In more than 40% patients, HCC developed in the absence of cirrhosis<sup>[69]</sup>. Comparable results were reported by different studies with different population groups<sup>[70-72]</sup>.

## TREATMENT AND OUTCOMES OF HCC IN THE BACKGROUND OF METABOLIC SYNDROME

Unfortunately there is no specific recommendation for treatment of HCC developing in the background of MetS. It is thought that HCC secondary to MetS may have better prognosis than its other counterparts partly because of early diagnosis with favorable prognostic markers. Because of lack of specific guidelines at present, HCC secondary to MetS are treated like HCC from other major associations. Insulin-sensitizing therapy may also improve the outcome of HCC. Metformin therapy is associated with lower mortality in diabetic patients with early stage HCC after radiofrequency ablation<sup>[73]</sup>. In another study, 100 diabetic patients with hepatitis C virus and cirrhosis were prospectively followed for 2.3-8.3 years and evaluated for the development of HCC, liver-related

death, or liver transplantation. The 5-year HCC development was lower in the group receiving metformin than in the group without metformin (9.5% *vs* 32.1%;  $P = 0.001$ ). Multivariate analysis showed that metformin treatment was independently associated with decreased HCC development (HR = 0.19;  $P = 0.023$ ) and liver-related death or transplantation in those patients (HR = 0.22;  $P = 0.049$ )<sup>[74]</sup>. Several other studies also demonstrated that the use of insulin-sensitizing agents in diabetes may reduce the risk of HCC development<sup>[75-77]</sup>. The role of rosuvastatin and ursodeoxycholic acid in the treatment of NASH or NAFLD and in prevention of NASH or NAFLD associated HCC is well studied<sup>[78,79]</sup>. A recent systematic review and meta-analysis showed a 50% reduction in HCC incidence with metformin use (OR = 0.50, 95%CI: 0.34-0.73). However, thiazolidinediones did not modify the risk of HCC (OR = 0.54, 95%CI: 0.28-1.02)<sup>[80]</sup>. Moreover, post-hoc analysis of randomized controlled trials did not reveal any significant association between antidiabetic medication use and risk of HCC although there was considerable heterogeneity across studies<sup>[80]</sup>.

## SURVEILLANCE FOR HCC IN METABOLIC SYNDROME

HCC still remains one of the malignancies with higher mortality ratio<sup>[2]</sup>. With better imaging studies, improvement of surgical techniques, and targeted therapy, the prognosis for early stage HCC is improving. But for advanced HCC the prognosis still remains poor. There are well established recommendations for surveillance of the patients with infectious risk factors and cirrhosis for HCC<sup>[81]</sup>. Evidence on metabolic syndrome as a risk factor for development of HCC, especially in the background of DM and obesity, is growing rapidly. With the ongoing epidemic of obesity, increased number of patients with DM, and the overall increase in the incidence and prevalence of MetS, it is imperative to identify the high risk groups for the development of HCC with MetS and provide appropriate surveillance strategies. The patients, who develop cirrhosis in the background of NAFLD, may be under surveillance as per current recommendations. But the question remains whether surveillance in patients who have NAFLD, without evidence of cirrhosis, is appropriate.

Most of the time, NAFLD will progress to cirrhosis before the development of HCC. But in a very small number of cases, it may progress to HCC without cirrhosis in the background of MetS. With about one third (34%) of the United States adult population meeting the criteria of MetS, surveillance for HCC may cause a significant health related economic issue in this regard<sup>[22]</sup>. But nevertheless, there should be an urgent and collaborative process to resolve this issue in the near future.

## SUMMARY

HCC is a common malignancy with dismal outcome.

The associations of HCC have been identified in great details. With the recent increase in the incidence of HCC without any indefinable causes, major efforts have been undertaken to identify more causative factors. The metabolic syndrome, especially with obesity and DM, has been implicated for the recent increase in HCC. Numerous basic science and clinical studies have shown a strong association between HCC and the metabolic syndrome. These studies have documented that NAFLD, to a large extent, is the hepatic manifestation of MetS and may progress to HCC through the cirrhotic process. It has also been shown that in a very small fraction of patients with NAFLD, HCC may develop without evidence of cirrhosis.

With the current epidemic of MetS, the number of patients with obesity and DM is increasing. Subsequently, it is expected that the incidence and prevalence of HCC will also increase. It is very important for the scientific community to shed more light on the pathogenesis of HCC with MetS, both with and without cirrhosis. At the same time it is also important to quantify the risk of HCC associated with the MetS in prospective setting and develop surveillance recommendations to detect HCC for patients with MetS.

## REFERENCES

- 1 **El-Serag HB**, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. *N Engl J Med* 1999; **340**: 745-750 [PMID: 10072408 DOI: 10.1056/NEJM199903113401001]
- 2 **International Agency for Research on Cancer**. GLOBOCAN 2008. Available from: URL: <http://globocan.iarc.fr>
- 3 **Gomaa AI**, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. *World J Gastroenterol* 2008; **14**: 4300-4308 [PMID: 18666317 DOI: 10.3748/wjg.14.4300]
- 4 **Salomao M**, Remotti H, Vaughan R, Siegel AB, Lefkowitz JH, Moreira RK. The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis. *Hum Pathol* 2012; **43**: 737-746 [PMID: 22018903 DOI: 10.1016/j.humpath.2011.07.005]
- 5 **Charlton M**, Angulo P, Chalasani N, Merriman R, Viker K, Charatcharoenwitthaya P, Sanderson S, Gawrieh S, Krishnan A, Lindor K. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. *Hepatology* 2008; **47**: 484-492 [PMID: 18220286]
- 6 **Siegel AB**, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. *Cancer* 2009; **115**: 5651-5661 [PMID: 19834957 DOI: 10.1002/cncr.24687]
- 7 **Bosch FX**, Ribes J, Cléries R, Díaz M. Epidemiology of hepatocellular carcinoma. *Clin Liver Dis* 2005; **9**: 191-211, v [PMID: 15831268 DOI: 10.1016/j.cld.2004.12.009]
- 8 **El-Serag HB**, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology* 2007; **132**: 2557-2576 [PMID: 17570226 DOI: 10.1053/j.gastro.2007.04.061]
- 9 **Adams LA**, Lindor KD. Nonalcoholic fatty liver disease. *Ann Epidemiol* 2007; **17**: 863-869 [PMID: 17728149 DOI: 10.1016/j.annepidem.2007.05.013]
- 10 **McCullough AJ**. Epidemiology of the metabolic syndrome in the USA. *J Dig Dis* 2011; **12**: 333-340 [PMID: 21091931 DOI: 10.1111/j.1751-2980.2010.00469.x]
- 11 **Ford ES**, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among u.s. Adults. *Diabetes Care* 2004; **27**: 2444-2449 [PMID: 15451914 DOI: 10.2337/diabetes.27.10.2444]
- 12 **Ford ES**, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. *JAMA* 2002; **287**: 356-359 [PMID: 11790215 DOI: 10.1001/jama.287.3.356]
- 13 **International Agency for Research on Cancer**. Cited 2013-01-07. Available from: URL: <http://globocan.iarc.fr/factsheet.asp>
- 14 **National Cancer Institute**. SEER Stat Fact Sheets: Liver and Intrahepatic Bile Duct. Available from: URL: <http://seer.cancer.gov/statfacts/html/livibd.html>
- 15 **Parkin DM**, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin* 2005; **55**: 74-108 [PMID: 15761078 DOI: 10.3322/canjclin.55.2.74]
- 16 **Morbidity and Mortality Weekly Report (MMWR)**. Hepatocellular Carcinoma - United States, 2001-2006. Cited 2013-02-02. Available from: URL: <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5917a3.htm>
- 17 **Alberti KG**, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 1998; **15**: 539-553 [PMID: 9686693]
- 18 **Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults**. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* 2001; **285**: 2486-2497 [PMID: 11368702 DOI: 10.1001/jama.285.19.2486]
- 19 **Alberti KG**, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. *Diabet Med* 2006; **23**: 469-480 [PMID: 16681555 DOI: 10.1111/j.1464-5491.2006.01858.x]
- 20 **Gu D**, Reynolds K, Wu X, Chen J, Duan X, Reynolds RF, Whelton PK, He J. Prevalence of the metabolic syndrome and overweight among adults in China. *Lancet* 2005; **365**: 1398-1405 [PMID: 15836888 DOI: 10.1016/S0140-6736(05)66375-1]
- 21 **Ervin RB**. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. *Natl Health Stat Report* 2009; (13): 1-7 [PMID: 19634296]
- 22 **Mokdad AH**, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991-1998. *JAMA* 1999; **282**: 1519-1522 [PMID: 10546690 DOI: 10.1001/jama.282.16.1519]
- 23 **Godfrey KM**, Sheppard A, Gluckman PD, Lillycrop KA, Burdge GC, McLean C, Rodford J, Slater-Jefferies JL, Garratt E, Crozier SR, Emerald BS, Gale CR, Inskip HM, Cooper C, Hanson MA. Epigenetic gene promoter methylation at birth is associated with child's later adiposity. *Diabetes* 2011; **60**: 1528-1534 [PMID: 21471513 DOI: 10.2337/db10-0979]
- 24 **Parkin DM**, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. *Int J Cancer* 2001; **94**: 153-156 [PMID: 11668491 DOI: 10.1002/ijc.1440]
- 25 **Borena W**, Strohmaier S, Lukanova A, Bjørge T, Lindkvist B, Hallmans G, Edlinger M, Stocks T, Nagel G, Manjer J, Engeland A, Selmer R, Häggström C, Tretli S, Concin H, Jonsson H, Stattin P, Ulmer H. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. *Int J Cancer* 2012; **131**: 193-200 [PMID: 21805476 DOI: 10.1002/ijc.26338]
- 26 **Baffy G**, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. *J Hepatol* 2012; **56**: 1384-1391 [PMID: 22326465 DOI: 10.1016/j.jhep.2011.10.027]
- 27 **Lazo M**, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. *Semin Liver Dis* 2008; **28**: 339-350 [PMID: 18956290 DOI: 10.1055/s-0028-1091978]



- 28 **Caldwell S**, Argo C. The natural history of non-alcoholic fatty liver disease. *Dig Dis* 2010; **28**: 162-168 [PMID: 20460906 DOI: 10.1159/000282081]
- 29 **Matteoni CA**, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. *Gastroenterology* 1999; **116**: 1413-1419 [PMID: 10348825 DOI: 10.1016/S0016-5085(99)70506-8]
- 30 **Browning JD**, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology* 2004; **40**: 1387-1395 [PMID: 15565570 DOI: 10.1002/hep.20466]
- 31 **Clark JM**, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. *Am J Gastroenterol* 2003; **98**: 960-967 [PMID: 12809815 DOI: 10.1111/j.1572-0241.2003.07486.x]
- 32 **2013 ASCO Annual Meeting**. Cited 2013-02-17. Available from: URL: [http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst\\_detail\\_view&confID=53&abstrctID=10464](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=53&abstrctID=10464)
- 33 **Caldwell SH**, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. *Gastroenterology* 2004; **127**: S97-103 [PMID: 15508109 DOI: 10.1053/j.gastro.2004.09.021]
- 34 **Nair S**, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? *Hepatology* 2002; **36**: 150-155 [PMID: 12085359 DOI: 10.1053/jhep.2002.33713]
- 35 **Larsson SC**, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. *Br J Cancer* 2007; **97**: 1005-1008 [PMID: 17700568]
- 36 **Chen CL**, Yang HL, Yang WS, Liu CJ, Chen PJ, You SL, Wang LY, Sun CA, Lu SN, Chen DS, Chen CJ. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. *Gastroenterology* 2008; **135**: 111-121 [PMID: 18505690 DOI: 10.1053/j.gastro.2008.03.073]
- 37 **Calle EE**, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. *N Engl J Med* 2003; **348**: 1625-1638 [PMID: 12711737 DOI: 10.1056/NEJMoa021423]
- 38 **Møller H**, Møller A, Lindvig K, Olsen JH. Obesity and cancer risk: a Danish record-linkage study. *Eur J Cancer* 1994; **30A**: 344-350 [PMID: 8204357 DOI: 10.1016/0959-8049(94)90254-2]
- 39 **Oh SW**, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. *J Clin Oncol* 2005; **23**: 4742-4754 [PMID: 16034050 DOI: 10.1200/JCO.2005.11.726]
- 40 **Welzel TM**, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. *Hepatology* 2011; **54**: 463-471 [PMID: 21538440 DOI: 10.1002/hep.24397]
- 41 **Siegel AB**, Lim EA, Wang S, Brubaker W, Rodriguez RD, Goyal A, Jacobson JS, Hershman DL, Verna EC, Zaretsky J, Halazun K, Dove L, Brown RS, Neugut AI, Kato T, Remotti H, Coppleson YJ, Emond JC. Diabetes, body mass index, and outcomes in hepatocellular carcinoma patients undergoing liver transplantation. *Transplantation* 2012; **94**: 539-543 [PMID: 22864187]
- 42 **Davila JA**, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. *Gut* 2005; **54**: 533-539 [PMID: 15753540 DOI: 10.1136/gut.2004.052167]
- 43 **Lagiou P**, Kuper H, Stuver SO, Tzonou A, Trichopoulos D, Adami HO. Role of diabetes mellitus in the etiology of hepatocellular carcinoma. *J Natl Cancer Inst* 2000; **92**: 1096-1099 [PMID: 10880555 DOI: 10.1093/jnci/92.13.1096]
- 44 **Schattenberg JM**, Schuppan D. Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. *Curr Opin Lipidol* 2011; **22**: 479-488 [PMID: 22002020]
- 45 **Wideroff L**, Gridley G, Møller M, Jensen L, Chow WH, Linet M, Kehn S, Borch-Johnsen K, Olsen JH. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. *J Natl Cancer Inst* 1997; **89**: 1360-1365 [PMID: 9308706 DOI: 10.1093/jnci/89.18.1360]
- 46 **El-Serag HB**, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. *Gastroenterology* 2004; **126**: 460-468 [PMID: 14762783 DOI: 10.1053/j.gastro.2003.10.065]
- 47 **Rosmorduc O**, Fartoux L. HCC and NASH: how strong is the clinical demonstration? *Clin Res Hepatol Gastroenterol* 2012; **36**: 202-208 [PMID: 22326764 DOI: 10.1016/j.clinre.2011.12.011]
- 48 **Turati F**, Talamini R, Pelucchi C, Polesel J, Franceschi S, Crispo A, Izzo F, La Vecchia C, Boffetta P, Montella M. Metabolic syndrome and hepatocellular carcinoma risk. *Br J Cancer* 2013; **108**: 222-228 [PMID: 23169288]
- 49 **Chen HF**, Chen P, Li CY. Risk of malignant neoplasms of liver and biliary tract in diabetic patients with different age and sex stratifications. *Hepatology* 2010; **52**: 155-163 [PMID: 20578004 DOI: 10.1002/hep.23641]
- 50 **Nagaoki Y**, Hyogo H, Aikata H, Tanaka M, Naeshiro N, Nakahara T, Honda Y, Miyaki D, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Takahashi S, Chayama K. Recent trend of clinical features in patients with hepatocellular carcinoma. *Hepatol Res* 2012; **42**: 368-375 [PMID: 22151896 DOI: 10.1111/j.1872-034X.2011.00929.x]
- 51 **Gaggini M**, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldello A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. *Nutrients* 2013; **5**: 1544-1560 [PMID: 23666091 DOI: 10.3390/nu5051544]
- 52 **Ahsan MK**, Okuyama H, Hoshino Y, Oka S, Masutani H, Yodoi J, Nakamura H. Thioredoxin-binding protein-2 deficiency enhances methionine-choline deficient diet-induced hepatic steatosis but inhibits steatohepatitis in mice. *Antioxid Redox Signal* 2009; **11**: 2573-2584 [PMID: 19764881 DOI: 10.1089/ars.2009.2385]
- 53 **Starley BQ**, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. *Hepatology* 2010; **51**: 1820-1832 [PMID: 20432259 DOI: 10.1002/hep.23594]
- 54 **Stickel F**, Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. *Gut* 2010; **59**: 1303-1307 [PMID: 20650925 DOI: 10.1136/gut.2009.199661]
- 55 **Tomimaru Y**, Koga H, Yano H, de la Monte S, Wands JR, Kim M. Upregulation of T-cell factor-4 isoform-responsive target genes in hepatocellular carcinoma. *Liver Int* 2013; **33**: 1100-1112 [PMID: 23651211 DOI: 10.1111/liv.12188]
- 56 **Bakiri L**, Wagner EF. Mouse models for liver cancer. *Mol Oncol* 2013; **7**: 206-223 [PMID: 23428636 DOI: 10.1016/j.molonc.2013.01.005]
- 57 **Ohki T**, Tateishi R, Shiina S, Goto E, Sato T, Nakagawa H, Masuzaki R, Goto T, Hamamura K, Kanai F, Yoshida H, Kawabe T, Omata M. Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH. *Gut* 2009; **58**: 839-844 [PMID: 19174415 DOI: 10.1136/gut.2008.164053]
- 58 **Bian Z**, Ma X. Liver fibrogenesis in non-alcoholic steatohepatitis. *Front Physiol* 2012; **3**: 248 [PMID: 22934006 DOI: 10.3389/fphys.2012.00248]
- 59 **Unger RH**, Clark GO, Scherer PE, Orci L. Lipid homeostasis, lipotoxicity and the metabolic syndrome. *Biochim Biophys Acta* 2010; **1801**: 209-214 [PMID: 19948243]
- 60 **Park EJ**, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Oster-

- reicher CH, Takahashi H, Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. *Cell* 2010; **140**: 197-208 [PMID: 20141834 DOI: 10.1016/j.cell.2009.12.052]
- 61 Ikejima K, Okumura K, Kon K, Takei Y, Sato N. Role of adipocytokines in hepatic fibrogenesis. *J Gastroenterol Hepatol* 2007; **22** Suppl 1: S87-S92 [PMID: 17567476 DOI: 10.1111/j.1440-1746.2007.04961.x]
- 62 Tawaramoto K, Kotani K, Hashiramoto M, Kanda Y, Nagare T, Sakaue H, Ogawa W, Emoto N, Yanagisawa M, Noda T, Kasuga M, Kaku K. Ablation of 3-phosphoinositide-dependent protein kinase 1 (PDK1) in vascular endothelial cells enhances insulin sensitivity by reducing visceral fat and suppressing angiogenesis. *Mol Endocrinol* 2012; **26**: 95-109 [PMID: 22108800 DOI: 10.1210/me.2010-0412]
- 63 Awazawa M, Ueki K, Inabe K, Yamauchi T, Kaneko K, Okazaki Y, Bardeesy N, Ohnishi S, Nagai R, Kadowaki T. Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway. *Biochem Biophys Res Commun* 2009; **382**: 51-56 [PMID: 19254698 DOI: 10.1016/j.bbrc.2009.02.131]
- 64 Cazanave SC, Mott JL, Elmi NA, Bronk SF, Werneburg NW, Akazawa Y, Kahraman A, Garrison SP, Zambetti GP, Charlton MR, Gores GJ. JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. *J Biol Chem* 2009; **284**: 26591-26602 [PMID: 19638343 DOI: 10.1074/jbc.M109.022491]
- 65 Torres DM, Harrison SA. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. *Semin Liver Dis* 2012; **32**: 30-38 [PMID: 22418886]
- 66 Yasui K, Hashimoto E, Komorizono Y, Koike K, Arai S, Imai Y, Shima T, Kanbara Y, Saibara T, Mori T, Kawata S, Uto H, Takami S, Sumida Y, Takamura T, Kawanaka M, Okanoue T. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. *Clin Gastroenterol Hepatol* 2011; **9**: 428-433; quiz e50 [PMID: 21320639 DOI: 10.1016/j.cgh.2011.01.023]
- 67 Takuma Y, Noso K. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. *World J Gastroenterol* 2010; **16**: 1436-1441 [PMID: 20333782 DOI: 10.3748/wjg.v16.i12.1436]
- 68 Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K, Shiratori K. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. *J Gastroenterol* 2009; **44** Suppl 19: 89-95 [PMID: 19148800 DOI: 10.1007/s00535-008-2262-x]
- 69 Duan XY, Qiao L, Fan JG. Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma. *Hepatobiliary Pancreat Dis Int* 2012; **11**: 18-27 [PMID: 22251466 DOI: 10.1016/S1499-3872(11)60120-3]
- 70 Chagas AL, Kikuchi LO, Oliveira CP, Vezozzo DC, Mello ES, Oliveira AC, Cella LC, Herman P, Bachella T, Caldwell SH, Alves VA, Carrilho FJ. Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients? *Braz J Med Biol Res* 2009; **42**: 958-962 [PMID: 19787150 DOI: 10.1590/S0100-879X2009005000019]
- 71 Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn WK, Canbay A. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. *Int J Cancer* 2011; **128**: 2436-2443 [PMID: 21128245 DOI: 10.1002/ijc.25797]
- 72 Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, Bedossa P, Belghiti J. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. *Hepatology* 2009; **49**: 851-859 [PMID: 19115377 DOI: 10.1002/hep.22734]
- 73 Chen TM, Lin CC, Huang PT, Wen CF. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. *J Gastroenterol Hepatol* 2011; **26**: 858-865 [PMID: 21251068 DOI: 10.1111/j.1440-1746.2011.06664.x]
- 74 Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I, Ganne-Carrie N, Grando-Lemaire V, Vicaut E, Trinchet JC, Beaugrand M. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. *J Clin Endocrinol Metab* 2011; **96**: 2601-2608 [PMID: 21752887 DOI: 10.1210/jc.2010-2415]
- 75 Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese JL, Vauthey JN. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. *Cancer* 2010; **116**: 1938-1946 [PMID: 20166205 DOI: 10.1002/cncr.24982]
- 76 Donadon V, Balbi M, Mas MD, Casarin P, Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. *Liver Int* 2010; **30**: 750-758 [PMID: 20331505 DOI: 10.1111/j.1478-3231.2010.02223.x]
- 77 Chen HP, Shieh JJ, Chang CC, Chen TT, Lin JT, Wu MS, Lin JH, Wu CY. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. *Gut* 2013; **62**: 606-615 [PMID: 22773548 DOI: 10.1136/gutjnl-2011-301708]
- 78 Nakahara T, Hyogo H, Kimura Y, Ishitobi T, Arihiro K, Aikata H, Takahashi S, Chayama K. Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. *Hepatol Res* 2012; **42**: 1065-1072 [PMID: 22583925 DOI: 10.1111/j.1872-034X.2012.01034.x]
- 79 Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. *Hepatology* 2004; **39**: 770-778 [PMID: 14999696 DOI: 10.1002/hep.20092]
- 80 Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. *Am J Gastroenterol* 2013; **108**: 881-891; quiz 892 [PMID: 23381014 DOI: 10.1038/ajg.2013.5]
- 81 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. *Hepatology* 2011; **53**: 1020-1022 [PMID: 21374666 DOI: 10.1002/hep.24199]

**P- Reviewers** Baffy G, Charatcharoenwithaya P,

Niculescu M, Sato K, Tulassay ZJ

**S- Editor** Wen LL **L- Editor** A **E- Editor** Liu XM





## GENERAL INFORMATION

*World Journal of Gastrointestinal Oncology* (*World J Gastrointest Oncol*, *WJGO*, online ISSN 1948-5204, DOI: 10.4251) is a peer-reviewed open access (OA) academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

### Aim and scope

*WJGO* covers topics concerning carcinogenesis, tumorigenesis, metastasis, diagnosis, prevention, prognosis, clinical manifestations, nutritional support, molecular mechanisms, and therapy of benign and malignant tumors of the digestive tract. The current contents of *WJGO* include editorial, frontier, diagnostic advances, therapeutics advances, field of vision, mini-reviews, review, topic highlight, medical ethics, original articles, case report, clinical case conference (Clinicopathological conference), and autobiography. Priority publication will be given to articles concerning diagnosis and treatment of gastrointestinal oncology diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJGO*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great clinical significance.

*WJGO* is edited and published by Baishideng Publishing Group (BPG). BPG has a strong professional editorial team composed of science editors, language editors and electronic editors. BPG currently publishes 42 OA clinical medical journals, including 41 in English, has a total of 15 471 editorial board members or peer reviewers, and is a world first-class publisher.

### Columns

The columns in the issues of *WJGO* will include: (1) Editorial: The editorial board members are invited to make comments on an important topic in their field in terms of its current research status and future directions to lead the development of this discipline; (2) Frontier: The editorial board members are invited to select a highly cited cutting-edge original paper of his/her own to summarize major findings, the problems that have been resolved and remain to be resolved, and future research directions to help readers understand his/her important academic point of view and future research directions in the field; (3) Diagnostic Advances: The editorial board members are invited to write high-quality diagnostic advances in their field to improve the diagnostic skills of readers. The topic covers general clinical diagnosis, differential diagnosis, pathological diagnosis, laboratory diagnosis, imaging diagnosis, endoscopic diagnosis, biotechnological diagnosis, functional diagnosis, and physical diagnosis; (4) Therapeutics Advances: The editorial board members are invited to write high-quality therapeutic advances in their field to help improve the therapeutic skills of readers. The topic covers medication therapy, psychotherapy, physical therapy, replacement therapy, interventional therapy, minimally invasive therapy, endoscopic therapy, transplantation therapy, and surgical therapy; (5) Field of Vision: The editorial board members are invited to write commentaries on classic articles, hot topic articles, or latest articles to keep readers at the fore-

front of research and increase their levels of clinical research. Classic articles refer to papers that are included in Web of Knowledge and have received a large number of citations (ranking in the top 1%) after being published for more than years, reflecting the quality and impact of papers. Hot topic articles refer to papers that are included in Web of Knowledge and have received a large number of citations after being published for no more than 2 years, reflecting cutting-edge trends in scientific research. Latest articles refer to the latest published high-quality papers that are included in PubMed, reflecting the latest research trends. These commentary articles should focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions. Basic information about the article to be commented (including authors, article title, journal name, year, volume, and inclusive page numbers); (6) Minireviews: The editorial board members are invited to write short reviews on recent advances and trends in research of molecular biology, genomics, and related cutting-edge technologies to provide readers with the latest knowledge and help improve their diagnostic and therapeutic skills; (7) Review: To make a systematic review to focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions; (8) Topic Highlight: The editorial board members are invited to write a series of articles (7-10 articles) to comment and discuss a hot topic to help improve the diagnostic and therapeutic skills of readers; (9) Medical Ethics: The editorial board members are invited to write articles about medical ethics to increase readers' knowledge of medical ethics. The topic covers international ethics guidelines, animal studies, clinical trials, organ transplantation, etc.; (10) Clinical Case Conference or Clinicopathological Conference: The editorial board members are invited to contribute high-quality clinical case conference; (11) Original Articles: To report innovative and original findings in gastrointestinal oncology; (12) Brief Articles: To briefly report the novel and innovative findings in gastrointestinal oncology; (13) Meta-Analysis: Covers the systematic review, mixed-treatment comparison, meta-regression, and overview of reviews, in order to summarize a given quantitative effect, e.g., the clinical effectiveness and safety of clinical treatments by combining data from two or more randomized controlled trials, thereby providing more precise and externally valid estimates than those which would stem from each individual dataset if analyzed separately from the others; (14) Case Report: To report a rare or typical case; (15) Letters to the Editor: To discuss and make reply to the contributions published in *WJGO*, or to introduce and comment on a controversial issue of general interest; (16) Book Reviews: To introduce and comment on quality monographs of gastrointestinal oncology; and (17) Autobiography: The editorial board members are invited to write their autobiography to provide readers with stories of success or failure in their scientific research career. The topic covers their basic personal information and information about when they started doing research work, where and how they did research work, what they have achieved, and their lessons from success or failure.

### Name of journal

*World Journal of Gastrointestinal Oncology*

### ISSN

ISSN 1948-5204 (online)



## Instructions to authors

### Launch date

October 15, 2009

### Frequency

Monthly

### Editorial-in-Chief

**Wasaburo Koizumi, MD, PhD, Professor, Chairman**, Department of Gastroenterology, Gastrointestinal Oncology, School of Medicine, Kitasato University, 2-1-1 Asamizodai Minamiku Sagamihara Kanagawa 252-0380, Japan

**Hsin-Chen Lee, PhD, Professor**, Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan

**Dimitrios H Roukos, MD, PhD, Professor**, Personalized Cancer Genomic Medicine, Human Cancer Biobank Center, Ioannina University, Metabatiko Ktirio Panepistimiou Ioanninon, Office 229, Ioannina, TK 45110, Greece

### Editorial Office

Jin-Lei Wang, Director

Xiu-Xia Song, Vice Director

*World Journal of Gastrointestinal Oncology*

Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China

Telephone: +86-10-59080039

Fax: +86-10-85381893

E-mail: [wjgo@wjgnet.com](mailto:wjgo@wjgnet.com)

<http://www.wjgnet.com>

### Publisher

Baishideng Publishing Group Co., Limited

Flat C, 23/F, Lucky Plaza, 315-321 Lockhart Road,  
Wanchai, Hong Kong, China

Telephone: +852-65557188

Fax: +852-31779906

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

### Production center

Beijing Baishideng BioMed Scientific Co., Limited  
Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China

Telephone: +86-10-85381892

Fax: +86-10-85381893

### Representative office

USA Office

8226 Regency Drive,

Pleasanton, CA 94588-3144, United States

Telephone: +1-925-2238242

Fax: +1-925-2238243

### Instructions to authors

Full instructions are available online at [http://www.wjgnet.com/1948-5204/g\\_info\\_20100312180518.htm](http://www.wjgnet.com/1948-5204/g_info_20100312180518.htm).

### Indexed and Abstracted in

PubMed Central, PubMed, Digital Object Identifier, and Directory of Open Access Journals.

## SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

### Biostatistical editing

Statistical review is performed after peer review. We invite an ex-

pert in Biomedical Statistics to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Ridit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

### Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJGO* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: [http://www.icmje.org/ethical\\_4conflicts.html](http://www.icmje.org/ethical_4conflicts.html).

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

### Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

### Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

## SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book

Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

### Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/esps/>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS ([http://www.wjgnet.com/1948-5204/g\\_info\\_20100312180518.htm](http://www.wjgnet.com/1948-5204/g_info_20100312180518.htm)) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to [wjgo@wjgnet.com](mailto:wjgo@wjgnet.com), or by telephone: +86-10-85381891. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

## MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

### Title page

**Title:** Title should be less than 12 words.

**Running title:** A short running title of less than 6 words should be provided.

**Authorship:** Authorship credit should be in accordance with the standard proposed by International Committee of Medical Journal Editors, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

**Institution:** Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

**Author contributions:** The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

**Supportive foundations:** The complete name and number of supportive foundations should be provided, e.g. Supported by National Natural Science Foundation of China, No. 30224801

**Correspondence to:** Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. [montgomery.bissell@ucsf.edu](mailto:montgomery.bissell@ucsf.edu)

**Telephone and fax:** Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g. Telephone: +86-10-85381891 Fax: +86-10-85381893

**Peer reviewers:** All articles received are subject to peer review. Normally, three experts are invited for each article. Decision on acceptance is made only when at least two experts recommend publication of an article. All peer-reviewers are acknowledged on Express Submission and Peer-review System website.

### Abstract

There are unstructured abstracts (no less than 200 words) and structured abstracts. The specific requirements for structured abstracts are as follows:

An informative, structured abstract should accompany each manuscript. Abstracts of original contributions should be structured into the following sections: AIM (no more than 20 words; Only the purpose of the study should be included. Please write the Aim in the form of "To investigate/study/..."), METHODS (no less than 140 words for Original Articles; and no less than 80 words for Brief Articles), RESULTS (no less than 150 words for Original Articles and no less than 120 words for Brief Articles; You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g.  $6.92 \pm 3.86$  vs  $3.61 \pm 1.67$ ,  $P < 0.001$ ), and CONCLUSION (no more than 26 words).

### Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

### Core tip

Please write a summary of less than 100 words to outline the most innovative and important arguments and core contents in your paper to attract readers.

### Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both. The main text format of these sections, editorial, topic highlight, case report, letters to the editors, can be found at: [http://www.wjgnet.com/1948-5204/g\\_info\\_list.htm](http://www.wjgnet.com/1948-5204/g_info_list.htm).

### Illustrations

Figures should be numbered as 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part

## Instructions to authors

should be added into the text where the figures are applicable. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...etc. It is our principle to publish high resolution-figures for the E-versions.

### Tables

Three-line tables should be numbered 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

### Notes in tables and illustrations

Data that are not statistically significant should not be noted. <sup>a</sup> $P < 0.05$ , <sup>b</sup> $P < 0.01$  should be noted ( $P > 0.05$  should not be noted). If there are other series of  $P$  values, <sup>c</sup> $P < 0.05$  and <sup>d</sup> $P < 0.01$  are used. A third series of  $P$  values can be expressed as <sup>e</sup> $P < 0.05$  and <sup>f</sup> $P < 0.01$ . Other notes in tables or under illustrations should be expressed as <sup>1</sup>F, <sup>2</sup>F, <sup>3</sup>F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, etc., in a certain sequence.

### Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

## REFERENCES

### Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability<sup>[1,2]</sup>". If references are cited directly in the text, they should be put together within the text, for example, "From references<sup>[19,22-24]</sup>, we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

### PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

### Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

### Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial let-

ter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). Book title. Publication number. Publication place: Publication press, Year: start page and end page.

### Format

#### Journals

*English journal article (list all authors and include the PMID where applicable)*

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

*Chinese journal article (list all authors and include the PMID where applicable)*

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarrhoea. *Shijie Huaren Xiaohua Zazhi* 1999; **7**: 285-287

*In press*

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

*Organization as author*

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 DOI:10.1161/01.HYP.0000035706.28494.09]

*Both personal authors and an organization as author*

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

*No author given*

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

*Volume with supplement*

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

*Issue with no volume*

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; **(401)**: 230-238 [PMID: 12151900 DOI:10.1097/0000-3086-200208000-00026]

*No volume or issue*

- 9 Outreach: Bringing HIV-positive individuals into care. *HRS-A Careaction* 2002; 1-6 [PMID: 12154804]

### Books

*Personal author(s)*

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

*Chapter in a book (list all authors)*

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

*Author(s) and editor(s)*

- 12 **Breedlove GK**, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wiecezorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

*Conference proceedings*

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

*Conference paper*

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computa-



tional effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

#### Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. *Emerg Infect Dis* serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

#### Patent (list all authors)

- 16 Pagedas AC, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

#### Statistical data

Write as mean  $\pm$  SD or mean  $\pm$  SE.

#### Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as  $\chi^2$  (in Greek), related coefficient as *r* (in italics), degree of freedom as *v* (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

#### Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h, blood glucose concentration, *c* (glucose)  $6.4 \pm 2.1$  mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6  $24.5 \mu\text{g/L}$ ; CO<sub>2</sub> volume fraction, 50 mL/L CO<sub>2</sub>, not 5% CO<sub>2</sub>; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, *etc.* Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantum numbers can be found at: [http://www.wjgnet.com/1948-5204/g\\_info\\_20100312183048.htm](http://www.wjgnet.com/1948-5204/g_info_20100312183048.htm).

#### Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

#### Italics

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg* 1, *c myc*, *c fos*, *etc.*

Restriction enzymes: *EcoRI*, *HindIII*, *BamHI*, *KhoI*, *KpnI*, *etc.*

Biology: *H. pylori*, *E. coli*, *etc.*

#### Examples for paper writing

All types of articles' writing style and requirement will be found in the

link: <http://www.wjgnet.com/esps/NavigationInfo.aspx?id=15>

## RESUBMISSION OF THE REVISED MANUSCRIPTS

Authors must revise their manuscript carefully according to the revision policies of Baishideng Publishing Group Co., Limited. The revised version, along with the signed copyright transfer agreement, responses to the reviewers, and English language Grade B certificate (for non-native speakers of English), should be submitted to the online system via the link contained in the e-mail sent by the editor. If you have any questions about the revision, please send e-mail to [esps@wjgnet.com](mailto:esps@wjgnet.com).

#### Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A.

#### Copyright assignment form

Please download a Copyright assignment form from [http://www.wjgnet.com/1948-5204/g\\_info\\_20100312182928.htm](http://www.wjgnet.com/1948-5204/g_info_20100312182928.htm).

#### Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: [http://www.wjgnet.com/1948-5204/g\\_info\\_20100312182841.htm](http://www.wjgnet.com/1948-5204/g_info_20100312182841.htm).

#### Proof of financial support

For papers supported by a foundation, authors should provide a copy of the approval document and serial number of the foundation.

## STATEMENT ABOUT ANONYMOUS PUBLICATION OF THE PEER REVIEWERS' COMMENTS

In order to increase the quality of peer review, push authors to carefully revise their manuscripts based on the peer reviewers' comments, and promote academic interactions among peer reviewers, authors and readers, we decide to anonymously publish the reviewers' comments and author's responses at the same time the manuscript is published online.

## PUBLICATION FEE

WJGO is an international, peer-reviewed, OA online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium and format, provided the original work is properly cited. The use is non-commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. Publication fee: 600 USD per article. All invited articles are published free of charge.



Published by **Baishideng Publishing Group Co., Limited**

Flat C, 23/F., Lucky Plaza, 315-321 Lockhart Road,

Wan Chai, Hong Kong, China

Fax: +852-65557188

Telephone: +852-31779906

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

